Veradermics, Inc (MANE)
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.
- Symbol
- MANE
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $4.69B
- 52 week range
- 32 - 131.24
Valuation
- Share price
- $115.78 (close of 2026-09-23)
- P/E (TTM)
- -2.45x
- Price to book
- 5.77x
- Price to free cash flow
- -72.60x
- Enterprise value
- $3.87B
- Book value per share
- $19.47
Price performance
| Period | Change |
|---|
| 1 day | +2.64% |
| 5 days | +11.44% |
| 1 month | +12.60% |
| 3 months | +11.76% |
| 6 months | +86.98% |
| All time | +206.70% |
Profitability and growth
- Return on equity
- 57.84%
- Return on assets
- -45.86%
- Return on capital employed
- -50.43%
- Net income growth
- -164.25%
- Free cash flow growth
- -202.37%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- -1.38%
- Current ratio
- 70.53x
- Net debt to EBITDA
- 9.29x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- EBITDA
- $-72.35M
- Net income
- $-70.00M
- Earnings per share
- $-111.91
- Research and development
- $62.06M
- Shares outstanding
- 744.99K
Income statement by year
| Period end | Net income | EPS |
|---|
| 2025-12-31 | $-70.00M | $-111.91 |
| 2024-12-31 | $-26.49M | $-37.05 |
Margins and returns by year
| Period end | Return on equity |
|---|
| 2025-12-31 | 57.84% |
| 2024-12-31 | 54.64% |
Cash and debt by year
| Period end | Cash |
|---|
| 2025-12-31 | $21.77M |
| 2024-12-31 | $53.08M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|
| 2025-12-31 | $-71.63M | $1.44M |
| 2024-12-31 | $-23.69M | $250.00K |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-10
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|
| 2026-08-11 | Jun/2026 | - |
| 2026-05-12 | - | - |
Filings and sources
- Company website
- veradermics.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Vertex Pharmaceuticals Inc (VRTX) · Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · Incyte Corp (INCY) · Bio-Techne Corp (TECH) · Thermo Fisher Scientific Inc. (TMO) · Danaher Corp (DHR) · IQVIA Holdings Inc. (IQV)
All Healthcare companies
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades